Mar 29 |
Adagene ADR Non-GAAP EPS of -$0.21, revenue of $18.11M
|
Mar 29 |
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
|
Mar 7 |
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
|
Feb 27 |
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
|
Feb 9 |
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-st...
|
Jan 19 |
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
|
Jan 18 |
How Is The Market Feeling About Adagene?
|
Jan 17 |
Adagene falls after trial data for cancer therapy
|
Jan 17 |
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
|
Jan 16 |
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
|